Given the recent FDA recommendation for a Phase 3 gene therapy trial for uniQure's investigational drug AMT-130, we wanted to address some of the topics and questions we have been receiving this week. Board members, researchers and family members, Emily Leestma and Lauren Byrne join Jenna Heilman for the discussion.

Breaking Down Barriers is sponsored by: uniQure, Ferrer, Prilenia, Neurocrine Biosciences, Teva Pharmaceutical, Skyhawk Therapeutics, Novartis and the Griffin Foundation.